objective: to compare side effects between users of two kinds of injectable contraceptives (depo-medroxy progesterone acetate and cyclofem). materials and methods: this cross-sectional descriptive study included 250 women, aged 18-40 years, using depo-medroxy progesterone acetate (dmpa) or cyclofem. the volunteers were examined six months after using contraceptive, and they were asked about fol...

BACKGROUND Oral contraceptives are known to influence the risk of cancers of the female reproductive system. Evidence regarding the relationship between injectable contraceptives and these cancers is limited, especially in black South Africans, among whom injectable contraceptives are used more commonly than oral contraceptives. METHODS AND FINDINGS We analysed data from a South African hospi...

OBJECTIVE To investigate factors associated with a woman's willingness to pay (WTP) for injectable contraceptives in Tigray, Ethiopia. METHODS We used a multistage random sampling design to generate a representative sample of reproductive age women from the Central Zone of Tigray, Ethiopia to participate in a survey (N = 1490). Respondents who had ever used injectable contraceptives or who we...

OBJECTIVE To determine whether community-based health workers in a rural region of Ethiopia can provide injectable contraceptives to women with similar levels of safety, effectiveness and acceptability as health extension workers (HEWs). METHODS This was a prospective non-randomized community intervention trial designed to test the provision of injectable contraceptives by community-based rep...

1. What exactly are injectable contraceptives, specifically DMPA and NET-EN? DMPA, or depot medroxyprogesterone acetate, and NET-EN, short for norethisterone enanthate, are contraceptives that contain a kind of hormone called progestin. Both are given by injection. DMPA (widely known by its marketed name Depo-Provera) is administered every three months, while NET-EN (or Noristerat) is given eve...

background: when family planning programmes offer a wide variety of contraceptives, contraceptive prevalence would be higher overall. objective: to determine the acceptability of cyclofem© and to evaluate its side effects and continuation rate in iran. materials and methods: an introductory study of cyclofem© was conducted in seven districts of kerman province, the largest province of iran, in ...

BACKGROUND In Sub-Saharan Africa, policy changes have begun to pave the way for community distribution of injectable contraceptives but sustaining such efforts remains challenging. Combining social marketing with community-based distribution provides an opportunity to recover some program costs and compensate workers with proceeds from contraceptive sales. This paper proposes a model for increa...

Depo-Provera® is depot medroxyprogesterone acetate (DMPA) aqueous suspension 150 mg in 1 ml formulated for deep IM injection. [2] This is most commonly used. Sayana Press® is DMPA 104 mg in 0.65 ml formulated for SC injection first licensed in the UK in 2011. [3] It is bio-equivalent to Depo-Provera®. It may be preferable to Depo-Provera® in women on anticoagulants or with a bleeding disorder. ...